High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer. [electronic resource]
Producer: 20020712Description: 105-10 p. digitalISSN:- 1465-3249
- Adult
- Aged
- Antigens, CD34 -- metabolism
- Blood Component Removal
- Blood Transfusion, Autologous -- adverse effects
- Breast Neoplasms -- blood
- Female
- Hematopoietic Stem Cell Mobilization
- Hematopoietic Stem Cell Transplantation -- adverse effects
- Humans
- Middle Aged
- Survival Rate
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.